Tradjenta bottle Tradjenta (linagliptin; Boehringer Ingelheim and Lilly) reduced blood sugar in adults with type 2 diabetes at risk for renal impairment, with a renal safety profile similar to that ...
Lilly and Boehringer Ingelheim’s diabetes collaboration saw its first approval as the FDA gave the green light to Boehringer’s Tradjenta (linagliptin) type 2 diabetes medication earlier this week. The ...
TRADJENTA (linagliptin) 5mg tablets by Boehringer Ingelheim and Eli Lilly Boehringer Ingelheim and Eli Lilly announced that the FDA has approved Tradjenta (linagliptin tablets), a dipeptidyl peptidase ...
First DPP-4 inhibitor approved at one dosage strength; no dose adjustment recommended for patients with type 2 diabetes who have kidney or liver impairment RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from three pooled analyses for ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of ...
RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Tradjenta™ (linagliptin) tablets are ...
The FDA's decision is based on data from a 52-week, phase 3 trial demonstrating the efficacy of TRADJENTA in combination with insulin (with or without metformin and/or pioglitazone). The trial results ...
Active ingredient: Linagliptin 5 mg; tabs. Indication: Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy. Pharmacology: Linagliptin is an inhibitor of DPP ...
(RTTNews) - Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with placebo on ...
INDIANAPOLIS — A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday. Lilly and BI announced the ...
The FDA has approved Tradjenta (linagliptin) tablets to control blood sugar in adults with diabetes type two – to be used along with diet and exercise, Boehringer Ingelheim Pharmaceuticals, Inc. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results